ATE462727T1 - An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese - Google Patents

An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese

Info

Publication number
ATE462727T1
ATE462727T1 AT03778499T AT03778499T ATE462727T1 AT E462727 T1 ATE462727 T1 AT E462727T1 AT 03778499 T AT03778499 T AT 03778499T AT 03778499 T AT03778499 T AT 03778499T AT E462727 T1 ATE462727 T1 AT E462727T1
Authority
AT
Austria
Prior art keywords
inhibiting angiogenesis
individual
polypeptides
binding antibodies
administering
Prior art date
Application number
AT03778499T
Other languages
English (en)
Inventor
Roy Bicknell
Vincent Birmingham
Steven Suchting
Lorna Mary Stewart
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32328072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE462727(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0227080A external-priority patent/GB0227080D0/en
Priority claimed from GB0321401A external-priority patent/GB0321401D0/en
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE462727T1 publication Critical patent/ATE462727T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT03778499T 2002-11-20 2003-11-20 An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese ATE462727T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0227080A GB0227080D0 (en) 2002-11-20 2002-11-20 Antibodies and uses thereof
GB0321401A GB0321401D0 (en) 2003-09-12 2003-09-12 Antibodies,polypeptides and uses thereof
PCT/GB2003/005059 WO2004046191A2 (en) 2002-11-20 2003-11-20 Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis

Publications (1)

Publication Number Publication Date
ATE462727T1 true ATE462727T1 (de) 2010-04-15

Family

ID=32328072

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03778499T ATE462727T1 (de) 2002-11-20 2003-11-20 An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese

Country Status (15)

Country Link
US (4) US20060099143A1 (de)
EP (1) EP1565491B1 (de)
JP (2) JP4869603B2 (de)
AT (1) ATE462727T1 (de)
AU (1) AU2003285500B8 (de)
CA (1) CA2506724C (de)
CY (1) CY1110661T1 (de)
DE (1) DE60331945D1 (de)
DK (1) DK1565491T3 (de)
HK (1) HK1080869A1 (de)
IL (2) IL168646A (de)
MX (1) MXPA05005470A (de)
PT (1) PT1565491E (de)
SI (1) SI1565491T1 (de)
WO (1) WO2004046191A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480622T1 (de) * 2000-11-06 2010-09-15 Cancer Rec Tech Ltd Bildgebende verfahren, diagnose und behandlung von krankheiten
US6926081B2 (en) * 2002-02-25 2005-08-09 Halliburton Energy Services, Inc. Methods of discovering and correcting subterranean formation integrity problems during drilling
EP2316853A3 (de) * 2002-03-08 2011-10-05 Shanghai Institutes for Biological Sciences, CAS Nachweis und modulation von slit- und robo-vermittelter angiogenese und ihre verwendung
JP4869603B2 (ja) * 2002-11-20 2012-02-08 キャンサー・リサーチ・テクノロジー・リミテッド 抗体、ポリペプチドおよびその使用
US8691780B2 (en) * 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
EP2104509A4 (de) * 2006-12-11 2010-03-24 Univ Utah Res Found Zusammensetzungen und verfahren zur behandlung von pathologischer angiogenese und gefässpermeabilität
EP2468776A3 (de) 2007-02-09 2012-11-14 Genentech, Inc. Antikörper gegen Robo4 und Anwendungen davon
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
ES2567030T3 (es) 2009-09-03 2016-04-19 Cancer Research Technology Limited Inhibidores de CLEC14A
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
KR101223511B1 (ko) * 2009-10-23 2013-01-31 주식회사 알앤엘바이오 지방조직 유래 성체 줄기세포 이동을 유도하는 방법
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
JP2013529076A (ja) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
EP2841457B1 (de) * 2012-04-27 2019-04-24 Daiichi Sankyo Company, Limited Anti-robo4-antikörper
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
WO2022221314A1 (en) * 2021-04-16 2022-10-20 BioLegend, Inc. Compositions and methods involving severe acute respiratory syndrome coronavirus 2 receptor binding domain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069007A (en) * 1989-06-21 2000-05-30 City Of Hope Ribozyme cleavage of HIV RNA
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
EP0682113A3 (de) 1994-05-12 1996-12-18 Ono Pharmaceutical Co Polypeptide hergestellt in einer Endothel Zell-Linie und dafür kodierende DNS.
US20040002591A1 (en) * 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
WO1999006423A1 (en) 1997-07-30 1999-02-11 Human Genome Sciences, Inc. 83 human secreted proteins
JP2001514024A (ja) 1997-09-05 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
US6225118B1 (en) * 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
EP1068312A2 (de) 1998-04-09 2001-01-17 Genset Humane 5' est's und kodierte proteine
CA2361840A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1074617A3 (de) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers für Synthese von ganzen-Länge cDNS und deren Anwendung
WO2001012671A1 (en) * 1999-08-12 2001-02-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr16
AU1190801A (en) 1999-09-30 2001-04-30 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
ATE480622T1 (de) * 2000-11-06 2010-09-15 Cancer Rec Tech Ltd Bildgebende verfahren, diagnose und behandlung von krankheiten
EP2316853A3 (de) * 2002-03-08 2011-10-05 Shanghai Institutes for Biological Sciences, CAS Nachweis und modulation von slit- und robo-vermittelter angiogenese und ihre verwendung
US20060160729A1 (en) 2002-06-27 2006-07-20 Li Dean Y Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
JP4869603B2 (ja) * 2002-11-20 2012-02-08 キャンサー・リサーチ・テクノロジー・リミテッド 抗体、ポリペプチドおよびその使用

Also Published As

Publication number Publication date
DK1565491T3 (da) 2010-07-19
CA2506724A1 (en) 2004-06-03
WO2004046191A2 (en) 2004-06-03
US20060263369A1 (en) 2006-11-23
AU2003285500A1 (en) 2004-06-15
IL168646A (en) 2010-12-30
US8394381B2 (en) 2013-03-12
AU2003285500B2 (en) 2010-07-01
US20080166295A1 (en) 2008-07-10
JP5336566B2 (ja) 2013-11-06
WO2004046191A3 (en) 2004-07-29
EP1565491A2 (de) 2005-08-24
CY1110661T1 (el) 2015-06-10
JP2006524485A (ja) 2006-11-02
JP4869603B2 (ja) 2012-02-08
AU2003285500B8 (en) 2011-02-03
EP1565491B1 (de) 2010-03-31
US20060099143A1 (en) 2006-05-11
US20080019963A1 (en) 2008-01-24
DE60331945D1 (de) 2010-05-12
IL204453A (en) 2014-02-27
JP2012050442A (ja) 2012-03-15
HK1080869A1 (en) 2006-05-04
PT1565491E (pt) 2010-07-06
SI1565491T1 (sl) 2010-08-31
MXPA05005470A (es) 2005-09-08
CA2506724C (en) 2013-03-12

Similar Documents

Publication Publication Date Title
HK1080869A1 (en) Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis
NO20063026L (no) Antistoffer
ATE475673T1 (de) Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
MX2012007318A (es) Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
UA96122C2 (ru) Антитело или его антигенсвязующий фрагмент, которое специфически связывается с il-22ra, и его применение
DK1572967T3 (da) IL-1-receptorbaserede antagonister og fremgangsmåder til fremstilling og anvendelse deraf
MX2009006659A (es) Anticuerpos y metodos de elaboracion y uso.
DE60310385D1 (de) Sekretion von proteinen mit mehreren disulfidbindungen in bakterien und verwendungen davon
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
ATE382060T1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DE69115917D1 (de) Humane gammainterferonantagonisten
AU2021278998A8 (en) Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC)
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
ATE386050T1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
RS52448B (en) ANTITUMOR PHARMACEUTICAL COMPOSITION CONTAINING SERALIZIN POLYPEPTIDE FRAGMENTS
ATE476447T1 (de) Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität
ATE423133T1 (de) Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
ATE449863T1 (de) Verwendung von lepa zur verbesserung der genauigkeit der in-vitro-proteinsynthese
DE60329492D1 (de) Produktion von rekombinanten fragmenten aus dem muskel-acetylcholinrezeptor und ihre verwendung für ex vivo immunabsorption von anti-ach-rezeptor antikörper bei patienten mit myasthenie
TW200619226A (en) Identification and characterization of function-blocking anti-Ed-B-fibronectin antibodies
DE60044136D1 (de) Tgf-alpha polypeptide, funktionelle fragmente und methoden zu deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1565491

Country of ref document: EP